John W. Smither's most recent trade in NewAmsterdam Pharma Company NV was a trade of 15,300 Option (right to buy) done . Disclosure was reported to the exchange on Jan. 7, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Co NV | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 15,300 | 15,300 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 3,400 | 10,360 | - | - | Ordinary Shares | |
| Genelux Corp | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2025 | 28,576 | 28,576 | - | - | Stock Option (Right to Buy) | |
| Genelux Corp | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2025 | 22,283 | 74,994 | - | 0 | Common Stock | |
| NewAmsterdam Pharma Co NV | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| Genelux Corp | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| Genelux Corp | Smither John W. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| Genelux Corp | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 39,541 | 52,711 | - | 0 | Common Stock | |
| Genelux Corp | John W. Smither | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 6,250 | 13,170 | - | - | Common Stock | |
| Genelux Corp | John W. Smither | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 6,250 | 6,250 | - | - | Common Stock Warrant (Right to Buy) | |
| Arcutis Biotherapeutics Inc | John Smither W. | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 25,718 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Smither W. John | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 8,572 | 11,365 (0%) | 0% | - | Common Stock | |
| Arcutis Biotherapeutics Inc | John Smither W. | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2024 | 8,379 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Smither W. John | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 2,793 | 2,793 (0%) | 0% | - | Common Stock | |
| NewAmsterdam Pharma Co NV | W. Smither John | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 10,000 | 10,000 | - | - | Option (right to buy) | |
| Applied Molecular Transpor... | W. Smither John | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 60,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | John W. Smither | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | Smither John W. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Dec 2023 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 36,875 | 36,875 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Applied Molecular Transpor... | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2021 | 24,142 | 24,142 | - | - | Common Stock | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2021 | 24,142 | 24,142 | - | - | Stock Option (Right to Buy) | |
| eFFECTOR Therapeutics Inc | John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2021 | 3,556 | 3,556 | - | - | Earn-out Right |